The Unitaid, Global Fund and Sanofi have jointly announced a new agreement to reduce the price of a critically important tuberculosis drug- rifapentine.
The agreement was announced at the 50th Union World Conference on Lung Health, which is being held in Hyderabad, India. The conference is convened by the International Union Against Tuberculosis and Lung Disease (The Union).
The agreement with Sanofi brings down the price of rifapentine (Priftin) 150mg tablets from €13.60 per pack of 24 tablets to a price of €4.62 per pack of 24 tablets, at a 66 percent discount.
The tablets will be available at the discounted price to the public sectors of low-income countries, lower-middle income countries, and upper-middle-income countries with a high burden of TB and TB-HIV, according to the company.
The announcement is followed by the declaration of Phase IIb trial analysis of the M72 TB vaccine candidate reported by pharmaceutical company GSK and the International AIDS Vaccine Initiative (IAVI).
“If we are to end the TB emergency, we need a prevention revolution,” says José Luis Castro, Executive Director of The Union, in the news release.
“It is indeed timely that we are seeing such promising movement on all facets of prevention – vaccines, drug prices and new drugs – now we need to ensure that going forward, preventing wherever we treat becomes the new normal.” he added.